February 2026 Options Now Available For Encompass Health (EHC)

Encompass Health Corp (EHC) is trading at $108.14 and Stock Options Channel highlights a $105 put (bid $1.00) and a $110 call (bid $2.50) as income strategies. Selling the $105 put would set an effective share basis of $104 and is ~3% OTM with a 65% chance to expire worthless, producing a 0.95% return (5.43% annualized YieldBoost). Selling the $110 covered call against existing shares would cap upside at $110 (≈2% OTM) with a 50% chance to expire worthless, yielding 2.31% (13.18% annualized) to Feb 2026. Implied vols are ~28% for the put and 27% for the call versus a 12-month realized volatility of 26%.

Analysis

Market structure: The immediate winners are option premium sellers and yield-seeking income accounts — selling the EHC Feb-2026 $105 put (collect ~$1, effective entry $104) or $110 covered calls (collect $2.50) monetizes a small IV premium (IV 27–28% vs realized 26%). Losers are pure momentum/long-only holders who face capped upside if covered calls are deployed; broker/clearing counterparty risk is minimal. The modest IV pick-up implies supply of options sellers > marginal buyer demand for protection, signaling short-term preference for income over directional exposure.

Risk assessment: Tail risks center on Medicare/CMS reimbursement changes (>~2% cuts would be material), regulatory probes or a sudden deterioration in referral volumes — low probability but could move shares >15% in weeks. Time horizons: options-decay yield accrues immediately (weeks→months), earnings and CMS rules are 1–6 month catalysts, while demographic-driven demand is a 2–5 year tailwind. Hidden dependency: assignment risk converts option P&L into equity exposure and ties up capital; rising rates could pressure financing-sensitive peers and widen credit spreads.

Trade implications: Execute small, size-controlled income trades: cash‑secured puts (EHC Feb-2026 $105) sized 1–3% portfolio to target ~5% realized IRR if assigned; covered calls (own EHC, sell Feb-2026 $110) on 25–50% of position to harvest ~4% upside+premium. If concerned about downside, construct collars (long $100 put, short $110 call) to cap risk to ~7–10% for defined cost. Prefer selling premium to buying volatility — IV is only slightly rich versus realized.

Contrarian angles: The market under-appreciates the value of assignment as a deliberate accumulation tool — selling the $105 put effectively bids stock at a 3% discount with a ~35% assignment probability; this can be superior to bidding the tape. Conversely, if CMS headlines reprice fundamentals, option sellers will be caught with concentrated equity exposure. Historical parallels (post-acute provider reactions to reimbursement noise) show transient 15–25% drawdowns followed by multi-quarter recoveries, favoring disciplined, size-limited income strategies over naked long exposure.

Key Decisions for Investors

• Sell cash‑secured EHC Feb‑2026 $105 puts sized at 1–3% of portfolio (collect ≈ $1, effective buy at $104). Risk controls: close or hedge if EHC < $98, IV > 35%, or position P&L loss >50%.
• If long EHC equity, sell Feb‑2026 $110 covered calls on 25–50% of holdings to capture ~4.0% gross return to $110 (13% annualized). Roll or buy back if EHC > $108 with <30 days to expiry to avoid forced assignment into earnings/CMS windows.
• If downside protection desired, buy a Feb‑2026 protective $100 put (or a $100/$95 put spread) sized to cap drawdown below ~$100; target hedging cost ≤2% of position value and hold through next CMS/earnings cycle (3–6 months).
• Watch these triggers over next 60–180 days and act: reduce option-seller sizing by 50% if CMS proposes cumulative post‑acute cuts ≥2% or if EHC reports sequential EBITDA miss >8%; increase allocation (up to additional 1–2% portfolio) to cash‑secured puts if shares retreat to ≤$95 with IV≥30%.